A report on the blog FiercePharma says the approval of blood thinner Eliquis in Europe has the manufacturers of competing medications “on their toes.”
Eliquis, from Pfizer and Bristol-Myers Squibb, was developed as an alternative to warfarin, which for decades has been the standard treatment for blood clot prevention.
But according to FiercePharma, warfarin “comes with a host of dosage-tweaking rules, plus interactions with alcohol and food, so it is difficult ...
continue reading...